Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes
Esposito, Katherine, Ciotola, Miryam, Carleo, Diego, Schisano, Bruno, Sardelli, Luigi, Di Tommaso, Domenico, Misso, Lucio, Saccomanno, Franco, Ceriello, Antonio and Giugliano, D. (Dario). (2008) Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. Journal of Clinical Endocrinology & Metabolism , Volume 93 (Number 4). pp. 1345-1350. ISSN 0021-972xFull text not available from this repository.
Official URL: http://dx.doi.org/10.1210/jc.2007-2000
Context: Two-hour postprandial hyperglycemia is related to chronic complications of diabetes and is currently used in the international guidelines to drive the therapy. Objective: Our objective was to assess the size and timing of post-meal glucose peaks in the everyday life of type 2 diabetic patients and the relationship with carotid atherosclerosis. Design, Setting, and Patients: This was an observational study performed in 644 outpatients with type 2 diabetes attending diabetes clinics located in the area of the Campania County, South Italy, who provided complete home blood glucose profiles and centralized carotid intima-media thickness (CIMT) assessment. The study was conducted from 2001-2005. Main Outcome Measures: Incremental glucose peak (IGP) was the maximal incremental increase in blood glucose obtained at any point after the meal. CIMT was assessed by carotid sonography. Results: The level of glycosylated hemoglobin and CIMT progressively increased across quintiles of IGP (P for trend = 0.01 for both). In univariate analysis, all examined glycemic parameters were significantly correlated with CIMT. IGP (r = 0.40; P = 0.006) showed the strongest correlation with CIMT, which remained significant in multiple linear regression analysis (R-2 = 0.26; P = 0.01). IGP was associated with a significant increase of CIMT in tertiles of glycosylated hemoglobin. IGP occurred within 1 h from the start of the meal in 95% of the entire diabetic population. Conclusion: IGPs are frequent in the everyday life of patients with type 2 diabetes, occur for most (95%) within 1 h after meal, timing of IGPs is not influenced by treatment (diet or drugs), and IGPs correlate with CIMT.
|Item Type:||Journal Article|
|Subjects:||R Medicine > RC Internal medicine|
|Divisions:||Faculty of Medicine > Warwick Medical School > Metabolic and Vascular Health
Faculty of Medicine > Warwick Medical School
|Library of Congress Subject Headings (LCSH):||Non-insulin-dependent diabetes, Hyperglycemia, Glycemic index|
|Journal or Publication Title:||Journal of Clinical Endocrinology & Metabolism|
|Number of Pages:||6|
|Page Range:||pp. 1345-1350|
|References:||1. International Diabetes Federation 2006 Available from www.idf.org 2. 1993 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group.NEngl J Med 329:977–986 3. 1995 The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44:968–983 4. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, ShichiriM1995 Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with noninsulin- dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103–117 5. 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).UKProspective Diabetes Study (UKPDS) Group. Lancet [Erratum (1999) 354:602] 352:837–853 6. Stettler C, Allemann S, Juni P, Cull CA, Holman RR, Egger M, Krahenbhul S, Diem P 2006 Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 152:27–38 7. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B 2006 Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29:1963–1972 8. Sorkin JD, Muller DC, Fleg JL, Andres R 2005 The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 28:2626–2632 9. Shiraiwa T, Kaneto H, Miyatsuka T, Kato K, Yamamoto K, Kawashima A, Kanda T, Suzuki M, Imano E, Matsuhisa M, Hori M, Yamasaki Y 2005 Postprandial hyperglycemia is a better predictor of the progression of diabetic retinopathy than HbA1c in Japanese type 2 diabetic patients. Diabetes Care 28:2806–2807 10. Levitan EB, Song Y, Ford ES, Liu S 2004 Is nondiabetic hyperglycemia a risk factor for cardiovascular disease?Ameta-analysis of prospective studies. Arch Intern Med 164:2147–2155 11. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, RuppM2004 Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25:10–16 12. Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, Nappo F, Lucarelli C, D’Onofrio F 1997 Vascular effects of acute hypergly- cemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 95:1783–1790 13. Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, Creager MA 1998 Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97:1695–1701 14. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D 2001 Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 108: 635–636 15. Scognamiglio R, Negut C, De Kreutzenberg SV, Tiengo A, Avogaro A 2005 Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation 112:179–184 16. 1996 The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 45:1289–1298 17. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, TurnerRC,HolmanRR2000Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412 18. Erlinger TP, Brancati FL 2001 Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. Diabetes Care [Erratum (2002) 25:249] 24:1734–1738 19. Bonora E, Corrao G, Bagnardi V, Ceriello A, Comaschi M, Montanari P, Meigs JB 2006 Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 49:846– 854 20. 2007 AACE Diabetes Mellitus Clinical Practice Guidelines Task Force, American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice of the Management of Diabetes Mellitus. Endocr Pract 13(Suppl 1): 5-68 21. 2006 Global guideline for type 2 diabetes. International Diabetes Federation Task Force on Clinical Guidelines, International Diabetes Federation. http:// www.idf.org 22. O’Leary LH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson Jr SK 1999 Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340:14–22 23. Esposito K, Giugliano D, Nappo F, Marfella R 2004 Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110:214–219 24. Zar JH 1999 Biostatistical analysis. 4th ed. Upper Saddle River, NJ: Prentice Hall Inc.; 663 25. 1999 A desktop guide to type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabet Med 16:716–730 26. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, HanefeldM 2000 Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c levels. Diabetes Care 23:1830–1834 27. Burke GL, Evans GW, Riley WA, Sharrett AR, Howard G, Barnes RW, Rosamond W, Crow RS, Rautaharju PM, Heiss G 1995 Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Stroke 26:386–391 28. Azen SP, Mack WJ, Cashin-Hemphill L, LaBree L, Shircore AM, Selzer RH, Blankenhom DH, Hodis HN 1996 Progression of coronary artery disease predicts clinical coronary events: long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 93:34–41 29. Weyer C, Bogardus C, Mott DM, Pratley RE 1999 The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787–794 30. Pratley RE, Weyer C 2001 The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 44:929–945 31. Monnier L, Collette C, Dunseath GJ, OwensDR2007 The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 30:263–269 32. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Va¨ha¨ talo M, Virtamo H, Nikkila¨ K, Tulokas T, Hulme S, Hardy K, McNulty S,Ha¨nninen J, Leva¨nen H, Lahdenpera¨ S, Lehtonen R, Ryysy L 2006 Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 49:442–451 33. Polonsky KS, Given BD, Van Cauter E 1988 Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 81:442–448 34. American Diabetes Association 2001 Postprandial blood glucose. American Diabetes Association. Diabetes Care 24:775–778 35. American Diabetes Association 2005 Standards of medical care in diabetes. Diabetes Care [Erratum (2005) 28:990] 28(Suppl 1):S4–S36 36. Gerich JE 2003 Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 163:1306–1316 37. Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, Anfossi G, Costa G, Trovati M 2006 Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 91:813–819 38. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, Kugiyama K, Ogawa H, Yasue H 1999 Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34:146–154 39. Ceriello A, Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A, Esposito K, Giugliano D 2004 Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 53:701–710 40. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C 2006 Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295: 1681–1687 41. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOPNIDDM Trial Research Group 2002 Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077 42. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOPNIDDM Trial Research Group 2004 Acarbose for the prevention of type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia 47:969–975 43. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova- Kurktschiev T 2004 Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 355: 1073–1078|
Actions (login required)